X

Trial Profile

A phase I study of combination therapy with WT1 peptide-pulsed dendritic cells and gemcitabine for advanced pancreatic and biliary tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 30 Apr 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gemcitabine (Primary) ; Tumour peptide-loaded dendritic cell vaccine Tella (Primary)
Indications Biliary cancer; Pancreatic cancer
Focus Adverse reactions

Most Recent Events

26 Apr 2018 Status changed from suspended to completed.
26 Jul 2014 Status changed from recruiting to suspended, as per University Hospital Medical Information Network - Japan record.
15 Jul 2011 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com